ATE246516T1 - Neue enzyme und prodrugs für adept - Google Patents

Neue enzyme und prodrugs für adept

Info

Publication number
ATE246516T1
ATE246516T1 AT95900827T AT95900827T ATE246516T1 AT E246516 T1 ATE246516 T1 AT E246516T1 AT 95900827 T AT95900827 T AT 95900827T AT 95900827 T AT95900827 T AT 95900827T AT E246516 T1 ATE246516 T1 AT E246516T1
Authority
AT
Austria
Prior art keywords
adept
prodrugs
enzymes
new enzymes
nucleic acid
Prior art date
Application number
AT95900827T
Other languages
English (en)
Inventor
Gary Keith Smith
Todd Andrew Blumenkopf
Michael Cory
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of ATE246516T1 publication Critical patent/ATE246516T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
AT95900827T 1993-11-12 1994-11-11 Neue enzyme und prodrugs für adept ATE246516T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939323429A GB9323429D0 (en) 1993-11-12 1993-11-12 Therapy
PCT/GB1994/002483 WO1995013095A2 (en) 1993-11-12 1994-11-11 Therapy

Publications (1)

Publication Number Publication Date
ATE246516T1 true ATE246516T1 (de) 2003-08-15

Family

ID=10745113

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95900827T ATE246516T1 (de) 1993-11-12 1994-11-11 Neue enzyme und prodrugs für adept

Country Status (15)

Country Link
US (2) US6140100A (de)
EP (1) EP0728018B1 (de)
JP (1) JPH09507834A (de)
AT (1) ATE246516T1 (de)
AU (1) AU688412B2 (de)
CA (1) CA2176024A1 (de)
DE (1) DE69433015T2 (de)
DK (1) DK0728018T3 (de)
ES (1) ES2204935T3 (de)
GB (1) GB9323429D0 (de)
IL (1) IL111601A0 (de)
MY (1) MY114140A (de)
NZ (1) NZ276137A (de)
WO (1) WO1995013095A2 (de)
ZA (1) ZA948987B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
GB2309033B (en) * 1994-12-23 1999-06-02 Zeneca Ltd Chemical compounds
KR100270650B1 (ko) * 1994-12-23 2000-11-01 돈 리사 로얄 돌연변이된 숙주효소를 이용한 항체-지시된 효소 전구약제 치료
PL325017A1 (en) * 1995-08-16 1998-07-06 Zeneca Ltd Chemical compounds
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
WO1999033870A2 (en) * 1997-12-31 1999-07-08 Incyte Pharmaceuticals, Inc. Human regulatory proteins
WO2001034779A2 (en) 1999-11-12 2001-05-17 Lexicon Genetics Incorporated Human proteins with homology to carboxypeptidases and polynucleotides encoding the same
AU2002216864A1 (en) * 2000-12-21 2002-07-01 Mcgill University Conjugates of antibodies and anticancer drugs
CA2458534C (en) 2001-09-14 2011-11-01 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
NZ596825A (en) 2002-07-15 2013-06-28 Univ Texas Duramycin peptides and their use in imaging
US20110002978A1 (en) * 2003-06-17 2011-01-06 Harrison Roger G Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof
US20080221303A1 (en) * 2004-02-18 2008-09-11 Jehoshua Katzhendler Method for the Preparation of Peptide-Oligonucleotide Conjugates
DK1794294T3 (da) * 2004-09-27 2011-10-31 Sanofi Aventis Deutschland Rekombinant carboxypeptidase B
WO2006059245A2 (en) * 2004-11-16 2006-06-08 Neurochem (International) Limited Compounds for the treatment of cns and amyloid associated diseases
EP2614837A1 (de) 2007-11-09 2013-07-17 Affitech Research AS Anti-VEGF-Antikörperzusammensetzungen und Verfahren
PL2491788T3 (pl) 2011-02-25 2016-07-29 Kraft Foods R & D Inc Wyrób spożywczy z formowanym korpusem
US9340504B2 (en) * 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
KR102137214B1 (ko) * 2013-12-17 2020-07-23 스텔라파머 가부시키가이샤 2-플루오로-4-보로노-l-페닐알라닌의 제조 방법 및 2-플루오로-4-보로노-l-페닐알라닌의 전구체
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
WO2020032951A1 (en) 2018-08-09 2020-02-13 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
WO2022272307A1 (en) * 2021-06-24 2022-12-29 Lycia Therapeutics, Inc. Bifunctional folate receptor binding compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5433955A (en) 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
KR0185967B1 (ko) * 1989-01-23 1999-05-01 에프. 쥐. 엠. 헤르만스; 에이. 쥐. 제이. 베르미렌 치료용 약물의 부위 특이적 생체내 활성작용
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
FI94362C (fi) * 1989-10-20 1995-08-25 Squibb Bristol Myers Co Oleellisesti puhdistettu sulfataasi, menetelmä sen valmistamiseksi ja sitä tuottava Streptomyces-kanta
GB9200415D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Inactivation of cytotoxic drugs
US6187579B1 (en) * 1993-10-28 2001-02-13 Carlsberg A/S Customized proteases
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5985627A (en) * 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase

Also Published As

Publication number Publication date
AU688412B2 (en) 1998-03-12
US6140100A (en) 2000-10-31
DE69433015D1 (de) 2003-09-11
NZ276137A (en) 1998-04-27
EP0728018B1 (de) 2003-08-06
JPH09507834A (ja) 1997-08-12
AU8148894A (en) 1995-05-29
DE69433015T2 (de) 2004-06-09
EP0728018A1 (de) 1996-08-28
IL111601A0 (en) 1995-01-24
MY114140A (en) 2002-08-30
ES2204935T3 (es) 2004-05-01
GB9323429D0 (en) 1994-01-05
DK0728018T3 (da) 2003-11-24
WO1995013095A2 (en) 1995-05-18
US6319702B1 (en) 2001-11-20
WO1995013095A3 (en) 1995-07-13
ZA948987B (en) 1996-05-13
CA2176024A1 (en) 1995-05-18

Similar Documents

Publication Publication Date Title
DE69433015D1 (de) Neue Enzyme und Prodrugs für ADEPT
PT659215E (pt) Producao de enzimas que degradam fitato em trichoderma
AU5753598A (en) Novel genes coding for amino acid deacetylases with specificity for N-acetyl-L-phosphinothricin, their isolation and use
CA2160131A1 (en) New Bacillus Thuringiensis Strains and Their Insecticidal Proteins
AU3926895A (en) Nucleic acid transfer system
ATE321866T1 (de) Mutierte 5-enolpyruvylshikimat-3-phosphat synthase, für dieses protein kodierendes gen und dieses gen enthaltende transformierte pflanzen
PT101297A (pt) Factores mitogenicos gliais, sua preparacao e utilizacao
AU7327596A (en) Preparation of phosphorothioate oligomers
BR0015114A (pt) Sequências de ácido nucléico e de aminoácido, construção de ácido nucleico, vetor, microorganismo, l-pantolactona hidrolase, e, processo para preparar d-pantolactona
DE69231745D1 (de) Gensequenzen kodierend für Flavonoid-Stoffwechselwegenzyme und deren Verwendung
DE69738942D1 (de) Genetische sequenzen, welche für enzyme des flavonoid-stoffwechselweges kodieren und deren anwendungen
AU1430097A (en) Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
MX9800719A (es) Proteinas de transporte y sus usos.
ATE490311T1 (de) Mutanten der alpha-amylase
DE69928121D1 (de) Verwendungen von sulfatierten fuko-oligosacchariden zum pflanzenschutz
HUP9800765A2 (hu) Kevésbé adszorbeálódó és fokozottan hidrolizáló szubtilizin Carlsberg variánsok
HUP9801638A2 (hu) Kevésbé adszorbeálódó és jobban hidrolizáló proteáz K variánsok
MX9700818A (es) Produccion bacteriana de polipeptidos hidrofobicos.
BG101892A (en) Sugar-modified cytostatics
HUP9800767A2 (hu) Kevésbé adszorbeálódó és jobban hidrolizáló szubtilizin DY variánsok
MX9703475A (es) D-pantolactona hidrolasa y gen que codifica para la misma.
EP1757684A3 (de) 2,6-Beta-D-Fruktanhydrolase Enzym und Verfahren zu dessen Verwendung
AU1719497A (en) An enzyme with pectin esterase activity
ZA982009B (en) Isolated nucleic acid molecules encoding SSX family members and uses thereof.
DE69631899D1 (de) Xylanasen, für diese kodierende gene und anwendungen derselben

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0728018

Country of ref document: EP

REN Ceased due to non-payment of the annual fee